Skip to main content
Clinical Trials/CTRI/2021/01/030482
CTRI/2021/01/030482
Completed
Phase 2

Clinical evaluation of anti-inflammatory and analgesic activities of AQUA-TURM® in Subjects Suffering from Osteoarthritis of Knee(s) - An Open Labelled, Multi-centre, Non-comparative, interventional, Prospective Study - NI

ODAAT PHARMA0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: M179- Osteoarthritis of knee, unspecified
Sponsor
ODAAT PHARMA
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
ODAAT PHARMA

Eligibility Criteria

Inclusion Criteria

  • 1\.History of knee pain due to osteoarthritis requiring use of NSAIDs, Acetaminophen, or another analgesic agent.
  • 2\.OA confirmed by radiographs and diagnosed according to ACR diagnostic criteria (clinical\+ radiological) for the osteoarthritis of the knee(s)
  • 3\.Knee joint(s) pain greater than or equal to 40 on Visual Analogue Scale (VAS).

Exclusion Criteria

  • 1\.Subjects with rheumatoid arthritis, gout, pseudo gout, inflammatory arthritis, Paget disease of bone, chronic pain syndrome, fibromyalgia, or another major joint disease
  • 2\.Subjects with history of surgery, including arthroscopy, or major trauma to the study joint in the previous six months before the screening visit
  • 3\.Subjects requiring knee arthroplasty within 6 months of screening or anticipating any need for a surgical procedure on the index joint during the study
  • 4\.Subjects with signs of clinically important active inflammation of the study knee joint including redness, warmth and or a large, bulging effusion with the loss of normal contour at the screening and/or baseline visits
  • 5\.Subjects using systemic corticosteroids within 2 months of screening, or intra\-articular visco\-supplementation within the past 3 months
  • 6\.Subjects with any other investigational drug within 1 month prior to randomization;
  • 7\.Subjects with uncontrolled diabetes mellitus and hypertension
  • 8\.Subjects with known tuberculosis, HIV, ischemic heart disease, cancer, kidney failure
  • 9\.Pregnant and lactating women
  • 10\.Subjects with significant abnormal laboratory parameters

Outcomes

Primary Outcomes

Not specified

Similar Trials